AtriCure, Inc.

AtriCure maintains a conservative capital structure with $146.2 million in cash and equivalents against $61.0 million in long-term debt, resulting in a low debt-to-equity ratio of 0.12. The balance sheet is highly liquid, evidenced by a current ratio of 4.29 and total equity of $491.7 million. Despite this strong liquidity position, the company generated negative operating cash flow of -$4.0 million and negative free cash flow of -$7.8 million in Q1 2026, driven by capital expenditures of $3.9 million. The company retains significant unused borrowing capacity of $62.8 million under its ABL facility, providing additional financial flexibility.

Profitability remains constrained as the company scales, with Q1 2026 revenue of $141.2 million yielding a gross profit of $109.3 million, implying a gross margin of approximately 77%. However, operating income was minimal at $0.5 million, and net income was $0.1 million, resulting in negative return on equity (-2.3%) and negative return on assets (-1.8%). The valuation snapshot reflects these early-stage profitability dynamics, with a price-to-book ratio of 8.13 and a negative EV/EBITDA of -172.9, while trading at 3.06x revenue.

Revenue generation is focused on expanding treatment options for atrial fibrillation and post-operative pain, with a strategy centered on global commercial expansion and new product launches. The company’s business model relies on the continued development of its technologies and the publication of additional scientific evidence to drive market acceptance and demand. While specific segment or geographic revenue breakdowns are not detailed in the available data, the strategic focus is clearly on broadening the addressable market for its core medical device offerings.

Growth trajectory is supported by a market capitalization of $1.72 billion and a mean analyst price target of $49.38, suggesting expectations for future expansion beyond current revenue levels. The company’s share count stands at 50.6 million basic shares, with diluted shares at 49.0 million, indicating limited immediate dilution from options or warrants in the current period. The negative free cash flow indicates that growth is currently capital-intensive, requiring ongoing investment in operations and capital expenditures.

Risk assessment highlights medium dilution risk, with source documents explicitly mentioning dilution or offering risks. The company’s Employee Stock Purchase Plan allows for the purchase of shares at a 15% discount, which introduces a structural dilution mechanism, although participant limits are capped at $25 per calendar year or 3 shares per offering period. Liquidity risk is assessed as low due to the strong cash position and high current ratio, but the negative cash flow generation requires monitoring to ensure sustainable operations without excessive equity issuance.

Recent events include the filing of an 8-K with material items under code 2.02, indicating a significant corporate event or agreement, though the specific nature is not detailed in the observation summary. Analyst sentiment is moderately positive, with a mean recommendation of 2.00 (Buy), supported by 2 strong buys and 6 buys against 2 holds. The company continues to emphasize forward-looking statements regarding earnings estimates, new product launches, and market acceptance as key drivers of future performance.

AtriCure generated $48.3 million in free cash flow for FY2025, demonstrating strong cash generation capabilities despite ongoing net losses.

The company maintains a low debt-to-equity ratio of 0.13, indicating a conservative capital structure with minimal leverage risk.

AtriCure holds a strong liquidity position with a current ratio of 3.96, ensuring ample short-term assets to cover liabilities.

Capital expenditures represent only 1.69% of revenue, placing the company in the bottom quartile for capex intensity within its cohort.

Return on equity of -2.33% matches the cohort median, suggesting performance is in line with peers despite negative profitability.

AtriCure faces high credit risk according to internal risk flags, signaling potential concerns regarding its creditworthiness or financial stability.

The company reported a net loss of $11.4 million in FY2025, continuing a trend of negative net income over the analyzed period.

Operating margin of -1.77% falls below the cohort median of 1.92%, indicating weaker operational profitability compared to peers.

Medium dilution risk is flagged, suggesting potential future equity issuance that could reduce existing shareholder value.

Cash conversion metric of -5.01 places the company in the bottom quartile of its cohort, reflecting poor cash generation efficiency.

Revenue $141.2M; Operating income $526.0k.

• ▍Revenue $141.2M
• ▍Operating income $526.0k
• ▍Net margin 0.1%

Revenue $394.0M; Operating income -$11.9M.

• ▍Revenue $394.0M
• ▍Operating income -$11.9M
• ▍Net margin -3.4%

Revenue $259.8M; Operating income -$12.1M.

• ▍Revenue $259.8M
• ▍Operating income -$12.1M
• ▍Net margin -5.0%

Revenue $534.5M; Operating income -$9.4M.

• ▍Revenue $534.5M
• ▍Operating income -$9.4M
• ▍Net margin -2.1%

Revenue $465.3M; Operating income -$40.0M.

• ▍Revenue $465.3M
• ▍Operating income -$40.0M
• ▍Net margin -9.6%

Revenue $465.3M; Operating income -$40.0M.

• ▍Revenue $465.3M
• ▍Operating income -$40.0M
• ▍Net margin -9.6%

Revenue $399.2M; Operating income -$26.7M.

• ▍Revenue $399.2M
• ▍Operating income -$26.7M
• ▍Net margin -7.6%